Clinical trial
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory…
NCT00485966 · Cylene Pharmaceuticals, Industry · Withdrawn
Key facts
| NCT number | NCT00485966 |
|---|---|
| Title | Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia |
| Official title | A Phase 2, Multi-Center, Open Label Study Evaluating Clinical Efficacy, Safety, and Pharmacodynamic Effects of Quarfloxacin (CX-3543) in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) |
| Lead sponsor | Cylene Pharmaceuticals, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-Cell Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | CX-3543 |
| Enrollment | 25 |
| Start date | Jun 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | Jun 13, 2007 |
| Last update posted | Nov 5, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: